Respiratory Tract Infections
|
In two separate
studies, we have seen that Wobenzym dramatically reduces the
sickness rate in children that
have frequent infections. The sickness rate in
Wobenzym-treated children was reduced by 65.2 % and
reduction of antibiotic consumption was 71.8 %. The
decreased need for antibiotics is of course impressive. On
average, the children were sick over 5 times a year before
taking Wobenzym. Atfer taking Wobenzym they got sick less
than twice a year. The Wobenzym-treated children also
benefited from not having elevated temperature and feeling
less tired. We should keep in mind, that in these cases the children were traditionally treated with antibiotics, but the course of the infection took long to resolve, and the patients had recurrent infections – they were in and out of the hospital over 5 times a year. Wobenzym is used as an adjuvant in these cases to make antibiotics more effective - but more importantly to improve immune function so that the patients did not keep getting sick. So Wobenzym acted as both an adjuvant and as an immunomodulator – restoring balance to the immune system. From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND Read the special section: RESPIRATORY CONDITIONS & WOBENZYM® |
What the literature says about Systemic Enzyme Support and:
Systemic enzyme therapy in the treatment of children with recurrent
infections of respiratory tract.
Vokálová I. Systemic enzyme therapy in the treatment of children
with recurrent infections of respiratory tract. VOX PEDIATRIAE 2003,
Vol. 2., No. 9, pp. 29 – 30. [Czech]
The
article summarizes a four-year-experience with use of systemic
enzyme therapy in the treatment of recurrent respiratory diseases in
children.
Efficacy of Wobenzym in the treatment of recurrent respiratory
infections was studied in children treated during 1997-1999 in the
pediatric and allergology and clinical immunology practice. 30
children, aged 3-15 years, showing a high sickness rate and
deviation of at least one of the tested immune parameters (reduced
IgA, IfM, IgG, CD3 or elevated IgE) were included into the study.
The most frequent diagnoses were recurrent bronchitis (15 children),
proven asthma bronchiale (6 children), and recurrent laryngitis (4
children) accompanied by rhinitis, pharyngitis, tonsillitis, and
otitis. 9 children suffered additionally from atopic eczema.
Children received Wobenzym at the daily dose of 1 coated tablet per
6 kg body weight. Daily dose was divided into 2-3 subdoses.
Treatment started in autumn and lasted for 6 months. Prior to the
start of Wobenzym treatment children underwent basic laboratory
examinations, smears from nose and throat, ORL examination, and
screening for basic parameters of cellular and humoral immunity.
Wobenzym treatment led to a reduction of recurrence and dyspnea
attacks in patients suffering from recurrent bronchitis. Moreover,
frequency of acute respiratory infections as well as number and
severity of dyspnea attacks decreased also in children with proven
asthma. In case of recurrent laryngitis patients there were
basically no more laryngeal dyspnea attacks observed, whereas prior
to the Wobenzym treatment nearly every banal respiratory infection
resulted into such attack. Even if the disease occurred, it’s
severity was mild and administration of corticoids, so far necessary
at each laryngitis attack, was not necessary anymore. In children
with atopic eczema, a marked improvement of skin condition was
observed and outlasted for several months after end of Wobenzym
therapy.
Before treatment, elevated levels of IgE were found in 50 %
patients. Wobenzym therapy resulted in reduction of primarily
elevated IgE levels in 93 % patients. IgA level before treatment was
elevated in 33 % of patients. Wobenzym treatment led to a IgA
normalization in 60 % patients. In 30 % patients IgA level
increased, although it did not reach the normal values, yet.
Furthermore, clinical documentation of another 109 patients treated
with Wobenzym in 1999-2001 was evaluated aiming to study the
efficacy of Wobenzym in the treatment of recurrent respiratory
diseases. Study group consisted of children up to 10 years – 74 %
(42 % children up to 6 years, 32 % children 6-10 years), 13 %
children and youth 10-18 years, 13 % patients older than 18 years.
The most frequent immunological deviations were elevation of IgE
levels (41 % patients) and decreased IgA levels (20% patients).
Patients used mainly Wobenzym, in some cases Phlogenzym. Treatment
duration was 6 months. Children used Wobenzym at the recommended
dosage, usual daily dose for adults was 3x 4-5 coated tablets. Daily
dose of Phlogenzym for adults was 3x2 tablets. In children,
Phlogenzym was preferred in the treatment of laryngitis.
Daily dose of Phlogenzym for children was 1 tablet per 10 kg body
weight.
Systemic enzyme therapy resulted in reduction of both frequency and
severity of diseases. Therefore, associated prescription of
antibiotics was also significantly reduced.
Regarding the laboratory results, reduction or normalization
of IgE values was found in 47 % enzyme-treated patients; lowered IgA
levels were adjusted in 64 % patients. Very interesting were the
results concerning ECP (eosinophil cationic protein) – a marker of
atopic inflammation.
Elevated ECP levels were measured in 20 patients (20 %) before start
of enzyme treatment. After the treatment, decrease of elevated ECP
levels was found in 18 out of 20 patients.
Summary of findings for individual diagnoses:
Recurrent tonsillitis – children repeatedly suffering from
tonsillitis and using antibiotics were first treated with
combination of antibiotics and Wobenzym. If the laboratory
examination performed at disease recurrence did not prove a
streptococcal tonsillitis, only Wobenzym and antipyretics were
administered. Tonsillitis course was gradually palliated, frequency
of disease attacks decreased and in number of patients disappeared
completely.
Recurrent laryngitis – systemic enzyme therapy suppressed laryngeal
dyspnea and through its immunoregulatory effect caused lowering of
sickness rate. Phlogenzym was often preferred in combination with
basal treatment.
Atopic eczema – positive effect of Wobenzym was reached by a
systemic effect on inflammatory process. However, an improvement of
skin condition was observed after long term (3 months)
treatment accompanied by further dietetic and regimen
measures. Improvement outlasted after discontinuation of therapy.
Asthma bronchiale – systemic enzyme therapy was a suitable
supplementary treatment, it reduced frequency of acute diseases and
often enabled to reduce a dosage of inhalation corticoids.
It
can be concluded that systemic enzyme therapy represents a novel
therapeutic modality helping in the treatment of children showing a
high sickness rate.
Poster Reference Number 51.
Therapeutic efficacy of Wobenzym in patients with focal pneumonia.
Shved M.I., Dubkova G.I. Therapeutic efficacy of
Wobenzym in patients with focal pneumonia. Visnik naukovych
doslidženij 1999, No. 2, pp. 79-82. [Russian abstract, Czech
abstract]
The
article provides the investigation of two treating methods (the
commonly-spread one and the other – combined with the Wobenzym)
influence upon the clinically-roentgen indications, immune activity,
and the condition of the lipid freeradicaloxidation in 51 patients
with the nidus pneumonia. There were determined such changes in
patient’s state: the decrease of the T-h and T-c lymphocytes, the
humoral immune part activation, the balance disturbances in the
antioxydative protective systems functioning. The complex therapy
with the Wobenzym gives a possibility to reach more effective
clinically-roentgen and laboratory sanation in short time period due
to normalization of the immune reactivity and processes of the lipid
freeradicaloxidation.
Key
words: nidus pneumonia, Wobenzym, lipid peroxidation, antioxydative
protective system, immune reactivity (status).
Systemic enzyme therapy as a helpful aid in the pediatric practice.
Hubková B. Systemic enzyme therapy as a helpful aid in the pediatric
practice. VOX PEDIATRIAE 2003: Roè. 3, è. 3, pp. 30 – 31. [Czech
abstract]
Based on first positive experience with Wobenzym treatment in
4-years old boy suffering from recurrent infections, systemic enzyme
therapy was successfully used also in other children showing a high
sickness rate, which were repeatedly treated with antibiotics.
37
children, aged 1,5 – 18 years,
included into the study used Wobenzym during 1999-2001 and
were evaluated during 12 months prior and after start of Wobenzym
treatment.
Sickness list in the evaluated group of children:
13
children with proven allergies, recurrent infections of respiratory
tract, including bronchitis (5 children with dermorespiratory
syndrome),
6
children with recurrent bronchitis without proven allergy,
5
children after severe pneumonias (3x atypical pneumonia),
4
children with recurrent tonsillitis,
4
children with recurrent renal and urinary tract diseases (2 children
with pyelonephritis and 2 children with cystitis),
2
children with recurrent laryngitis,
1
child with recurrent otitis,
2
children with recurrent viral infections showing a severe course.
Children were treated
with Wobenzym at the daily dose of 1 coated tablet per 6 kg body
weight. The dosage was divided into 2 daily doses and administered
on empty stomach. Small children who were unable to swallow the
whole tablet used crushed tablets strictly on empty stomach with
plenty of water. Daily dosage was divided into 2 doses. Daily dose
in these cases was increased to 1 coated tablet per 4 kg body
weight.
Prior to the start of systemic enzyme therapy, children underwent
basic laboratory examination, blood count + …………, immunoglobulins,
and other necessary examinations associated with the individual
diseases. Children were in most cases treated for 6 months from
autumn to spring. During Wobenzym treatment as well as six months
prior and after the treatment children received no immunostimulatory
drugs.
For
study evaluation, a mean sickness rate in Wobenzym-treated children
was observed within 12 months prior the treatment and next 12 months
after the start of treatment. This period consisted of 6 months of
Wobenzym treatment followed by 6 months of no treatment.For
comparison purposes, a mean annual sickness rate in all children in
the practice during last 3 years was calculated. All diseases,
including diarrheal ones accompanied by fever higher than 37.2 °C,
infectious diseases with or without fever (e.g. varicella), attacks
of allergic cough, pollinoses without
fever where a current medication was insufficient, were
included into the evaluation. Injuries were excluded.
A
total annual sickness rate in 1999 was 3.8, in 2000 - 4.2, and in
2001 - 3.2.
Thus, a mean annual sickness rate calculated for the above three
years was 3.7.
One
year before start of Wobenzym treatment each out of 37 observed
children got sick 5.4 times a year.
During the year of Wobenzym treatment the same patients got
sick only 1.8 times a year. Even more interesting were the results
showing consumption of antibiotics necessary to treat the disease.
One year before Wobenzym treatment, the children used antibiotics in
total of 71 cases, whereas 1 year after start of Wobenzym treatment
it was just 20 cases. Therefore, a sickness rate in Wobenzym-treated
children was reduced by 65.2 % and reduction of antibiotic
consumption was 71.8 %.
Very interesting results were obtained in small children using
crushed tablets.
This in principle non lege artis mode of administration of tablets
resistant to gastric juices was chosen after thorough consideration
in patients suffering from recurrent laryngitis which did not
respond to any other treatment options. Therapeutic effect was seen
also in such administered crushed Wobenzym tablets, laryngitis does
not recur anymore. Although in one patient first laryngitis
recurrence occurred 13 months after the start of Wobenzym treatment,
disease course was mild and easily treatable.
Significant improvement in skin condition was observed in five
patients with dermorespiratory syndrome. However, it should be
mentioned that the improvement was seen after long-term Wobenzym
treatment – at least 8 weeks. Reduction of allergic manifestations,
such as nose obstruction and burning eyes during pollen season which
persisted even under treatment with antihistamines, was observed in
children with proven pollinoses under Wobenzym treatment. Children
used concomitantly Wobenzym and current antihistamine preparations.
In comparison to the treatment with other immunostimulatory drugs,
Wobenzym-treated children benefited from not having elevated
temperature and being tired.
Based on the above mentioned findings it can be concluded that
systemic enzyme therapy may serve as a very helpful aid in the
treatment of children showing a high sickness rate. Sickness rate is
reduced as well as a necessity to use antibiotics. In chronically
sick children Wobenzym represents a suitable supplementary
treatment.